Resonance Health is actively involved in exploring and promoting awareness of the risk of iron toxicity and fatty liver in cancer survivors, which has resulted from cancer treatment regimes. We are working with healthcare providers, patient advocacy groups, health institutions, and patients, to assist with the provision of optimal patient care. Recently, we have attended two conferences targeted towards cancer survivorship; the Cancer Survivorship Summit in the UK and the Cancer Survivor Meeting in the USA.
The Cancer Survivorship Summit held in London in February was attended by our Marketing Director, Melanie Baxter, and UK Representative, Susanna Katay-Davis; who networked with a diverse group of delegates including haematologists, surgeons, consultants, clinical nurses, service commissioners, and patients. There was significant interest in the topic of iron toxicity in cancer survivors.
The team gauged interest in iron monitoring for transfused cancer survivors, collected further data on current practice, and was able to learn more about National Health Service (NHS) of England priorities and initiatives in the area of cancer survivorship. The NHS aims to improve practice and outcomes for those living with and beyond cancer. Together with the national cancer support organisation, Macmillan, the NHS is distributing ‘Recovery Packages’ to survivors to ensure that they have access to the care they need. We will continue to collaborate with the clinical teams to tailor optimal treatment regimens and further explore the potential to add FerriScan and HepaFat-Scan to NHS initiatives and guidelines on the management of cancer survivors.
Resonance Health’s Research Consultant & Account Manager, Alison Laws, and US-based Global Consultant, Sheila Murphy, attended the second annual Cancer Survivorship Symposium in San Diego in January. The conference was a collaboration between oncologists and primary care providers to enhance communications between care teams for cancer survivors. The conference provided Resonance Health with a number of significant opportunities for strategic networking with clinicians, patients, patient advocacy groups, and the American Society of Clinical Oncology (ASCO) itself. We see a significant opportunity in collaborating with ASCO to include assessment of iron overload into the guidelines for survivorship care. Contact was also made with several key patient advocacy groups and we intend to leverage these to raise patient awareness of iron toxicity and FerriScan. In addition, key contact with clinicians was made with the intention of furthering these relationships in order setup FerriScan at new sites to improve accessibility.